Lamivudine

Author:Prof. Dr. med. Peter Altmeyer

Last updated on: 29.10.2020

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).

Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Virustatic.

Half-lifeThis section has been translated automatically.

10–15 h

Pharmacodynamics (Effect)This section has been translated automatically.

Nucleoside analogue, competitive inhibitor of the reverse transcriptase of HIV.

IndicationThis section has been translated automatically.

Combination therapy of HIV infection, usually with a PI or NNRTI. Compensated chronic hepatitis B (in adults), decompensated hepatitis B (in adults).

Dosage and method of useThis section has been translated automatically.

HIV infection (Epivir): Pat. > 12 LJ: 2 times/day 150 mg p.o. or 1 time/day 300 mg p.o.
Pat. > 3 months - 12 LJ: 2 times/day 4 mg/kg bw (max. 300 mg/day).
Hepatitis (Zeffix): 100 mg/day p.o.

Remember! Dose adjustment necessary in case of reduced creatinine clearance.

Undesirable effectsThis section has been translated automatically.

Allergic exanthema, nausea, insomnia, headache, fever, fatigue, diarrhea, abdominal pain, neutropenia, anemia.

InteractionsThis section has been translated automatically.

Cotrimoxazole leads to an increase in lamivudine levels.

ContraindicationThis section has been translated automatically.

Children with a history of pancreatitis, lactation.

PreparationsThis section has been translated automatically.

Epivir, Zeffix

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer